CD47 and glioblastoma: oHSV expressing anti(α)-human CD47 IgG1 or IgG4 antibody were capable of blocking CD47, an immune checkpoint in glioblastoma cells, thereby decreasing local tumor size and improving survival in murine models of glioblastoma79.